Robert W. Azelby's most recent trade in Adc Therapeutics SA was a trade of 12,600 Common Shares done at an average price of $3.6 . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adc Therapeutics SA | Robert W. Azelby | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.58 per share. | 13 Jun 2025 | 12,600 | 80,405 | - | 3.6 | 45,108 | Common Shares |
| Adc Therapeutics SA | Robert W. Azelby | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 40,000 | 93,005 | - | 0 | Common Shares | |
| Terns Pharmaceuticals Inc | Robert W. Azelby | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Cardinal Health | Robert W. Azelby | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2024 | 1,730 | 3,018 (0%) | 0% | 0 | Common Shares | |
| Adc Therapeutics SA | Robert W. Azelby | Director | Sale of securities on an exchange or to another person at price $ 2.89 per share. | 17 Jun 2024 | 6,995 | 53,005 | - | 2.9 | 20,216 | Common Shares |
| Adc Therapeutics SA | Robert W. Azelby | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 40,000 | 60,000 | - | 0 | Common Shares | |
| Cardinal Health | Robert W. Azelby | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 1,288 | 1,288 (0%) | 0% | 0 | Common Shares | |
| Climb Bio Inc. | Robert W. Azelby | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Climb Bio Inc. | Robert W. Azelby | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) |